This is an Untapped Market
People In the United States Suffer From Osteoarthritis
14-55
Age Range: Aimed at Younger Patients Suffering from OA
The Growing Hip Preservation Market is worth Billions
Our Technology?
Expertise and Innovation
Sign up for Business News
Questions
About the
Technology?
Expertise and Innovation
Sign up for Business News
News
Newsletter – January 2024
The January 2024 issue of the CytexOrtho newsletter covers our 2023 accomplishments, including receiving Breakthrough Device Designation from the FDA, and highlights what is on the horizon in 2024: the plan for hosting our first clinical trial and the launch of our...
Newsletter – June 2023
The June issue of the CytexOrtho newsletter covers our successful crowdfunding raise, our progress toward clinical trials, and our talk on capitol hill! If you would like to receive a copy of our future newsletters, be sure to sign up for our mailing lists via the...
CytexOrtho on Capital Hill
On May 11th, 2023 Dr Brad Estes, CytexOrtho Co-founder and CEO, traveled to Washington D.C. to sit on a panel about the state of osteoarthritis (OA) in the United States, and the need for additional funding to move scientific advances combating OA to the clinic. The...
News
Newsletter – January 2024
The January 2024 issue of the CytexOrtho newsletter covers our 2023 accomplishments, including receiving Breakthrough Device Designation from the FDA, and highlights what is on the horizon in 2024: the plan for hosting our first clinical trial and the launch of our...
Newsletter – June 2023
The June issue of the CytexOrtho newsletter covers our successful crowdfunding raise, our progress toward clinical trials, and our talk on capitol hill! If you would like to receive a copy of our future newsletters, be sure to sign up for our mailing lists via the...
CytexOrtho on Capital Hill
On May 11th, 2023 Dr Brad Estes, CytexOrtho Co-founder and CEO, traveled to Washington D.C. to sit on a panel about the state of osteoarthritis (OA) in the United States, and the need for additional funding to move scientific advances combating OA to the clinic. The...